Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma

NCT03535259 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

86

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma, Radiotherapy, Sorafenib

Interventions

RADIATION: concurrent sorafenib and IMRT, followed sorafenib maintenance

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences